Counting major investors and global companies among its key clients, the Gibson, Dunn & Crutcher team regularly handles multijurisdictional investments in the tech, healthcare, and media sectors. Wim De Vlieger and Federico Fruhbeck co-head the outfit, both specialising in complex buy-out transactions, IPOs, and cross-border M&A. Regarded as 'an exceptional partner’ Till Lefranc is an expert in growth capital investments. Robert Dixon focuses on joint ventures, while Jeremy Kenley is knowledgeable on disposals and leveraged buyouts.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘The team's industry knowledge is excellent and a real asset to potential clients in better understanding industry standards for key VC/growth equity terms. These terms are in a constant state of flux, so the Gibson team's commercial awareness, stemming from their own experience and breadth of coverage of the VC/PE market, adds real value to us throughout the investment process. Breadth of practice areas including corporate, IP, ESG/Sustainability, etc. is a significant strength too, especially as the majority of our investments involve or will involve cross-border elements, complex IP, and Article 9 or SFDR-related parameters.'

  • 'While working with Gibson thus far, we have truly felt the direct benefits of a full-service firm, and the team has been willing to involve specialists across the firm as and when required - always in a timely manner.’

  • ‘We work most closely with Till Lefranc, who we have found to be an exceptional partner as we conduct our diligence and execute our investments. His commercial awareness has genuinely proven to be an advantage for us in competitive buyside processes, and his responsiveness and willingness to step in have made working with him an extremely efficient process. He has always been willing to go above and beyond our immediate requests to provide helpful context or market colour, and is very quick to anticipate second- and third-order consequences.’

  • ‘Strong partner representation and deep growth equity asset class knowledge.’

  • ‘Till Lefranc is highly available, efficient, and a value-add partner to our firm.’

Key clients

  • KKR
  • RedBird Capital Partners
  • Novator Ventures
  • Blue Earth Capital AG
  • Otro Capital
  • Dawn Biopharma
  • Frontier Biosolutions
  • Biosynth Carbosynth
  • Argenta
  • Clinisupplies

Practice head

The lawyer(s) leading their teams.

Wim De Vlieger, Federico Fruhbeck

Other key lawyers

Robert Dixon, Jeremy Kenley, Till Lefranc, Selina Sagayam, Mark Sperotto, Nick Tomlinson, Isabel Berger, Alice Brogi, Claibourne Harrison, Patrick Hennessy, Amar Madhani